RxDoctor Payments Data

Kimberly Davis-Seagle, MD

Internal Medicine · Mount Pleasant, SCNPI 1265408967

Payments from drug & device makers

$884in general payments, 2019–2025

Across 42 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$218
  • AstraZeneca$134
  • Pfizer$72
  • Medtronic$66
  • Boehringer Ingelheim$49
  • Vanda Pharmaceuticals Inc.$47
  • plus $297 from 13 others

What the payments were for

  • Food & beverage$884100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$884 in reported general payments places this provider in the 65th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$85,971
Medicare patients
209
Services billed
1,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$41,099
OzempicSemaglutide24$29,342
TrulicityDulaglutide20$15,248
MyrbetriqMirabegron27$14,397
Repatha SureclickEvolocumab17$13,444
XareltoRivaroxaban16$13,075
JanuviaSitagliptin Phosphate14$12,883
FarxigaDapagliflozin Propanediol13$9,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,084
Rosuvastatin Calcium292$4,695
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$4,677
SymbicortBudesonide/Formoterol Fumarate11$4,557
SynthroidLevothyroxine Sodium66$3,689
Irbesartan108$3,492
Solifenacin Succinate24$2,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$41,09957 claims
Novo NordiskOzempic$18$29,34224 claims
Lilly USA, LLCTrulicity$12$15,24820 claims
Astellas Pharma US IncMyrbetriq$17$14,39727 claims
AstraZenecaFarxiga, Symbicort$134$13,74824 claims
GSKTrelegy Ellipta$42$8,08413 claims
AbbVieSynthroid$44$3,68966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Mount Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →